These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31464130)

  • 1. Organoruthenated Nitroxoline Derivatives Impair Tumor Cell Invasion through Inhibition of Cathepsin B Activity.
    Mitrović A; Kljun J; Sosič I; Uršič M; Meden A; Gobec S; Kos J; Turel I
    Inorg Chem; 2019 Sep; 58(18):12334-12347. PubMed ID: 31464130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of endopeptidase and exopeptidase activity of cathepsin B impairs extracellular matrix degradation and tumour invasion.
    Mitrović A; Mirković B; Sosič I; Gobec S; Kos J
    Biol Chem; 2016 Jan; 397(2):165-74. PubMed ID: 26565553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin B inhibitors: Further exploration of the nitroxoline core.
    Sosič I; Mitrović A; Ćurić H; Knez D; Brodnik Žugelj H; Štefane B; Kos J; Gobec S
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1239-1247. PubMed ID: 29503024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of Novel Nitroxoline Analogs with Potent Cathepsin B Exopeptidase Inhibitory Activity.
    Van de Walle T; Briand M; Mitrović A; Sosič I; Gobec S; Kos J; Persoons L; Daelemans D; De Jonghe S; Ubiparip Z; Desmet T; Van Hecke K; Mangelinckx S; D'hooghe M
    ChemMedChem; 2020 Dec; 15(24):2477-2490. PubMed ID: 32744405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clioquinol-ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity.
    Mitrović A; Kljun J; Sosič I; Gobec S; Turel I; Kos J
    Dalton Trans; 2016 Nov; 45(42):16913-16921. PubMed ID: 27711842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity.
    Mirković B; Markelc B; Butinar M; Mitrović A; Sosič I; Gobec S; Vasiljeva O; Turk B; Čemažar M; Serša G; Kos J
    Oncotarget; 2015 Aug; 6(22):19027-42. PubMed ID: 25848918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
    Varshosaz J; Fard MM; Mirian M; Hassanzadeh F
    Anticancer Agents Med Chem; 2020; 20(3):346-358. PubMed ID: 31566137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
    Sosič I; Mirković B; Arenz K; Stefane B; Kos J; Gobec S
    J Med Chem; 2013 Jan; 56(2):521-33. PubMed ID: 23252745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel mechanism of cathepsin B inhibition by antibiotic nitroxoline and related compounds.
    Mirković B; Renko M; Turk S; Sosič I; Jevnikar Z; Obermajer N; Turk D; Gobec S; Kos J
    ChemMedChem; 2011 Aug; 6(8):1351-6. PubMed ID: 21598397
    [No Abstract]   [Full Text] [Related]  

  • 10. The Critical Role of Proteolytic Relay through Cathepsins B and E in the Phenotypic Change of Microglia/Macrophage.
    Ni J; Wu Z; Peterts C; Yamamoto K; Qing H; Nakanishi H
    J Neurosci; 2015 Sep; 35(36):12488-501. PubMed ID: 26354916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro.
    Premzl A; Zavasnik-Bergant V; Turk V; Kos J
    Exp Cell Res; 2003 Feb; 283(2):206-14. PubMed ID: 12581740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
    Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
    J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategy in inhibition of cathepsin B, a target in tumor invasion and metastasis.
    Lim IT; Meroueh SO; Lee M; Heeg MJ; Mobashery S
    J Am Chem Soc; 2004 Aug; 126(33):10271-7. PubMed ID: 15315439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of novel cathepsin-X inhibitors in vitro and in vivo and their ability to improve cathepsin-B-directed antitumor therapy.
    Mitrović A; Završnik J; Mikhaylov G; Knez D; Pečar Fonović U; Matjan Štefin P; Butinar M; Gobec S; Turk B; Kos J
    Cell Mol Life Sci; 2022 Jan; 79(1):34. PubMed ID: 34989869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
    Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
    Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current stage of cathepsin B inhibitors as potential anticancer agents.
    Kos J; Mitrović A; Mirković B
    Future Med Chem; 2014 Jul; 6(11):1355-71. PubMed ID: 25163003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular cystatin SN and cathepsin B prevent cellular senescence by inhibiting abnormal glycogen accumulation.
    Oh SS; Park S; Lee KW; Madhi H; Park SG; Lee HG; Cho YY; Yoo J; Dong Kim K
    Cell Death Dis; 2017 Apr; 8(4):e2729. PubMed ID: 28383558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells.
    Chan-On W; Huyen NT; Songtawee N; Suwanjang W; Prachayasittikul S; Prachayasittikul V
    Drug Des Devel Ther; 2015; 9():2033-47. PubMed ID: 25897210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of cathepsin B.
    Frlan R; Gobec S
    Curr Med Chem; 2006; 13(19):2309-27. PubMed ID: 16918357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.
    Duivenvoorden HM; Rautela J; Edgington-Mitchell LE; Spurling A; Greening DW; Nowell CJ; Molloy TJ; Robbins E; Brockwell NK; Lee CS; Chen M; Holliday A; Selinger CI; Hu M; Britt KL; Stroud DA; Bogyo M; Möller A; Polyak K; Sloane BF; O'Toole SA; Parker BS
    J Pathol; 2017 Dec; 243(4):496-509. PubMed ID: 29086922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.